Jpmorgan Chase & CO Adaptimmune Therapeutics PLC Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ADAP
# of Institutions
83Shares Held
150MCall Options Held
60.8KPut Options Held
5.8K-
Matrix Capital Management Company, LP Waltham, MA37.7MShares$22.6 Million1.71% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$16.4 Million1.13% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$10.2 Million1.24% of portfolio
-
Baillie Gifford & CO16.8MShares$10.1 Million0.01% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR13.3MShares$7.98 Million0.46% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $98M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...